Thursday, 21 Mar 2019

You are here

AURA-LV Trial - Voclosporin Effective in Lupus Nephritis

The AURA-LV trial assessed voclosporin, a calcineurin inhibitor in patients with active lupus nephritis (LN) and found that low-dose voclosporin may be successfully added to mycophenolate mofetil and corticosteroids to controll active LN.

A total of 265 lupus nephritis patients were enrolled from 79 worldwide centers in this Phase 2, randomized, double-blind, placebo-controlled trial of two doses of voclosporin (23.7 mg or 39.5 mg, given twice daily) versus placebo in patients already taking mycophenolate and steroids.  The primary endpoint was CRR at 24 weeks; the secondary endpoint was CRR at 48 weeks.

By week 24, a complete renal response (CRR) was achieved in 27-32% on voclosporin and 19% in the placebo group.  A significantly higher CRR rate was seen in the low-dose voclosporin group out to 48 weeks.

Serious adverse events were higher in the voclosporin and more deaths in the low-dose group compared to placebo and high-dose voclosporin groups.

These data sugggest the efficacy of low dose voclosporin in LN but adverse events may limit its ultimate fate.

More trials are in progress.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Improved Mortality Trends in Lupus Nephritis

The mortality rate from end- stage renal disease (ESRD) in lupus nephritis (LN) patients has significantly decreased in the last decade.

Cyclosporin and IVIG Effective in Kawasaki's Disease

A Lancet study has shown that adding cyclosporin to intravenous immunoglobulin (IVIG) Kawasaki disease patients, who were predicted to be resistant to IVIG, was both safe and effective in averting severe coronary artery outcomes.

Brazilian Guidelines for Systemic Autoimmune Myopathies

The Myopathy Committee of the Brazilian Society of Rheumatology (BSR) has put forward recommendations for the management of patients with systemic autoimmune myopathies (SAM).

The challenge has been that there is a paucity of effective controlled clinical trials, and hence, glucocorticoids (GC) have played a first-line and prominent role in the treatment of SAM.

EULAR Consensus Guidelines for Juvenile Localized Scleroderma

A EULAR international committee of 15 experts in pediatric rheumatology have established consensus-based recommendations for the management of juvenile localised scleroderma (JLS).

JLS is an uncommon disorder that is commonly seen by pediatric and adult rheumatologists. Evidence-based guidelines are sparse and management is mostly based on physicians’ experience.

2018 Swedish Guidelines for Giant Cell Arteritis Treatment

The Swedish Society of Rheumatology has developed evidence-based guidelines for the management of giant cell arteritis (GCA) with a focus on the appropriate use of corticosteroids and tocilizumab.